OPKO Health, CAMP4 Therapeutics Ink Oligonucleotide Platform With Focus On Drug-Resistant Epilepsy
- OPKO Health Inc (NASDAQ: OPK) has entered into an exclusive worldwide agreement with privately-held CAMP4 Therapeutics Corporation (CAMP4) to develop, manufacture, and commercialize therapeutics utilizing the AntagoNAT technology.
- AntagoNATs are oligonucleotide compounds that target non-coding natural antisense transcripts leading to an upregulation of a desired functional protein.
- CAMP4 has prioritized OPKO's lead AntagoNAT compound to progress into clinical trials for Dravet syndrome.
- Under the terms of the agreement, OPKO will receive an upfront payment and shares of CAMP4.
- In addition, OPKO will be eligible to receive up to $93.5 million and additional shares as milestone payments. CAMP4 will also pay OPKO double-digit royalties on product sales.
- Price Action: OPK shares are down 2.25% at $3.92 during the market session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs epilepsyBiotech News Penny Stocks Health Care Contracts General
